EWTX | Edgewise Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	14.91 - 16.54
52 Week Range	10.60 - 38.12
Beta	0.59
Implied Volatility	89.13%
IV Rank	12.77%
Day's Volume	1,172,301
Average Volume	1,787,181
Shares Outstanding	105,141,000
Market Cap	1,724,312,400
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-03-26

Valuation
Profitability
Growth
Health
P/E Ratio	-11.31
Forward P/E Ratio	N/A
EPS	-1.45
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	108
Country	USA
Website	EWTX

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

EWTX's peers: ACET, AGEN, ALXO, ATAI, AVTX, BCLI, BMEA, CCCC, CELC, CGEM, CLDX, CLSD, CNTA, CORT, CYCC, CYTK, DBVT, DYAI, DYN, ENTA, EQ, ERAS, IPSC, MLYS, TALS, VOR, IKNA, DSGN, XLO, ELYM, HOWL, DBTX, TCRR, RVMD, BDTX, BCEL, PASG, FBRX, FDMT, FENC, FHTX, FOLD, GBIO, GLTO, GMAB, GNFT, HALO, HRMY, IFRX, IMTX, IMUX, CYBN, INSM, IVA, JANX, JSPR, KALV, KRON, KROS, KYMR, LGVN, LVTX, LYEL, MDXG, MGNX, MGTX, MNMD, MOLN, MRKR, MRVI, NVCT, ORIC, PGEN, PMVP, PRAX, PRTG, RDUS, RLAY, RLMD, RLYB, SLDB, SNDX, SVRA, SYBX, THTX, TNGX, TRDA, TYRA, URGN, VALN, VERA, VIGL, VRCA, VTVT, XBIT, XENE, XNCR, XOMA, YMAB, HLVX, PEPG, QNCX, THRD, IVVD, PROK, OABI, GRI

*Chart delayed

Analyzing fundamentals for EWTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see EWTX Fundamentals page.

Watching at EWTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on EWTX Technicals page.